Lpa Forum

#Cardiologists, #Lipidologists, #Clinicians, it's #LpaAwarenessDay! Look on @LpaForum at our latest slide deck - Elevated Lp(a): Who is at risk? and accompanying expert commentary from Dr Jaimini Cegla >> lpaforum.org/back-to-basics… #KnowLpa @imperialcollege

With Lp(a) levels elevated in approximately 20% of the population, Professor Keith Ferdinand (@Tulane University School of Medicine) highlights the importance of testing #Lpa this #LpaAwarenessDay. Watch his video on @LpaForum > lpaforum.org/videos/video/t… #KnowLpa #ASCVD #LpaTesting

Don’t miss our latest updates on @LpaForum about the importance of Lp(a) testing to identify those at increased risk of #CVD who could benefit from more intensive #lipidlowering treatment. Find out more about who, why and when to test >> lpaforum.org #LpaAwarenessDay

☝️March 24 – Lp(a) Awareness Day 📍We routinely measure what we can treat. But we’re still ignoring what we must not miss. 👉Lp(a) is causal. 👉Lp(a) is genetic. 👉Lp(a) is present from birth. 📍1 in 5 people carry elevated levels— yet >98% have never been tested. ☝️No symptoms. No warning. First event? Often too late. 📍We talk about precision medicine… and still overlook one of the most powerful inherited drivers of cardiovascular risk. This isn’t a knowledge gap. It’s an action gap. One test. Once in a lifetime. No excuses left. 🙌Follow us on: instagram.com/soc.arg.lipido… @society_eas @fhpatienteurope @LipidosSal @Lipoproteina_ instagram.com/reel/DWQCiOxgB…

US clinicians are being urged to measure Lp(a) concentration at least once in their patients’ lives in new guidelines from the American College of Cardiology and the American Heart Association. Find out more on @LpaForum >> lpaforum.org/new-us-dyslipi… @ACCinTouch @American_Heart #Lpa

Next in the @LpaForum 𝗕𝗮𝗰𝗸 𝘁𝗼 𝗕𝗮𝘀𝗶𝗰𝘀 slide decks is 𝗘𝗹𝗲𝘃𝗮𝘁𝗲𝗱 𝗟𝗽(𝗮): 𝗪𝗵𝗼 𝗶𝘀 𝗮𝘁 𝗿𝗶𝘀𝗸? Download the slides and watch 𝗗𝗿 𝗝𝗮𝗶𝗺𝗶𝗻𝗶 𝗖𝗲𝗴𝗹𝗮's accompanying expert video commentary here > lpaforum.org/back-to-basics… #Lpa #cvrisk @imperialcollege

Read about a sensitive, high-throughput, immunocapture-based assay for direct quantification of Lp(a)-C that has been validated for potential use in research studies and clinical trials on @LpaForum >> lpaforum.org/validation-for… #lpa #cholesterol @Lpa_Doc lpaforum.org/validation-for…

👉 Lipoprotein(a) [Lp(a)] exemplifies antagonistic pleiotropy at its most unforgiving: a trait that improves early survival while silently programming cardiovascular disease decades later. 1️⃣ Lp(a) represents a case of evolutionary negligence rather than physiological design, a molecular workaround tolerated by natural selection because its harm is delayed and therefore irrelevant to reproductive fitness. 2️⃣ Its remarkably high population prevalence (~20–25%), pronounced ethnic skewing—with substantially higher levels in individuals of African ancestry—and the absence of any detectable phenotype in individuals with near-zero Lp(a) dismantle the argument of biological necessity. 3️⃣ The extraordinarily restricted phylogenetic distribution of Lp(a)—confined to humans, a subset of simians, and hedgehogs—rules out evolutionary conservation and instead points to a late, lineage-specific improvisation, adopted under selective pressure and never subsequently refined. 4️⃣ By co-opting the plasminogen scaffold, apolipoprotein(a) likely conferred early-life advantages in hemostasis, wound stabilization, and innate immune defense, functions that mattered when trauma and infection—not atherosclerosis—were the dominant threats to survival. 5️⃣ The atherothrombotic and valvular toxicity of elevated Lp(a) emerges only decades later, after reproductive success has been secured, exposing evolution’s indifference to cardiovascular longevity. 👆 Modern cardiology is correcting what evolution never bothered to fix @society_eas @nationallipid @Lpa_Doc @Drlipid @Lpa_CARE

Lp(a) is a key independent risk factor for #ASCVD and aortic valve stenosis. Explore the new Back to Basics slide deck from @LpaForum—𝗪𝗵𝗮𝘁 𝗶𝘀 𝗟𝗽(𝗮)?, plus 𝗲𝘅𝗽𝗲𝗿𝘁 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝗮𝗿𝘆 from Prof. John Chapman >> lpaforum.org/back-to-basics… #Lpa @nationallipid @Inserm

About 1 in 5 Canadians have high Lp(a), with higher risk in South Asian vs European groups. New Lp(a) screening framework urges more data on Indigenous peoples and calls for Lp(a) in first lipid panel. Read more on @LpaForum >> lpaforum.org/practical-fram… #Lpatesting #cvrisk #cardiologists #lipidologists #GPs #pharmacists #cardiacnurses

New ways to analyse oxidised phospholipids (OxPL-apoB & OxPL-apo(a)) on #Lpa are validated for clinical, translational & pharmacological research—supporting their potential as biomarkers of oxidative #lipid burden in Lp(a) lowering studies. lpaforum.org/oxpl-apob-and-… #cardioTwitter

Introducing What is Lp(a)? — the first Back to Basics slide deck on @LpaForum. Explore key advances in Lp(a) science, CV risk, and plaque progression, plus expert video insights from Prof. John Chapman... lpaforum.org/back-to-basics… #LpA #ASCVD #cardioTwitter #MedEd @EliLillyandCo

New research highlights the need to make #Lpa testing more widely available across Latin America, with clearer guidelines on including Lp(a) in #CVrisk assessment. Read more: lpaforum.org/lpa-perception… #cardiologists #lipidologists #cardiacnurses #GPs #pharmacists @drpablocorral

Prof. Keith Ferdinand highlights the need for more inclusive #Lpa research and care for under-represented groups at high #cardiovascularRisk. With Lp(a)-lowering therapies in Phase 3, he stresses reaching these patients now. Watch now >> lpaforum.org/videos/video/h… #HealthEquity

We have another advance today to translate @OxPL_apoB to research studies. Please see the CLIA validation of OxPL-apoB and OxPL-apo(a) jlr.org/article/S0022-… These assays will be useful in understanding results of the phase 3 Lp(a) trials and will complement @BostonHeartDX for clinical use. We hope to have OxPL-apo(a) also available for patient use in 2026.

As 2025 comes to a close, we’re reflecting on a year of important scientific advances and encouraging clinical insights published on @LpaForum. From deepening our understanding of Lp(a) biology to highlighting important new clinical data. Read more on >> lpaforum.org

Professor Steve Nissen (@ClevelandClinic) reviews new Phase 2 data on Lp(a) therapies #lepodisiran (#siRNA) & #muvalaplin, plus ongoing trials—and what this could mean for future practice. Watch on @LpaForum >> lpaforum.org/expert-meeting… #Lpa #CVD #lepodisiran #muvalaplin

Watch @DrM_ODonoghue, @BrighamWomens present extensive #olpasiran data from the Phase 2 OCEAN(a)-DOSE trial, and discuss progress with the ongoing Phase 3 OCEAN(a)-OUTCOMES and OCEAN(a)-PreEvent trials at the 2nd expert meeting of the @LpaForum > lpaforum.org/expert-meeting… #Lpa #CVD

In his new video, Professor Steve Nissen, @ClevelandClinic, discusses the Phase 3 Lp(a)HORIZON cardiovascular outcomes trial of #pelacarsen, and reviews results from the Lp(a)FRONTIERS APHERESIS trial on @LpaForum >> lpaforum.org/expert-meeting… #Lpa #ASCVD #LpaHORIZON @CleClinicMD